Tests early letters to encourage follow-up colonoscopy after a positive bowel cancer screening test
Tests early letters and leaflets to encourage colonoscopy after a positive bowel cancer screening test.
Key facts
- Who runs it
- University Hospital, Caen
- Where
- Tours, FranceSee the site
- Trial code
- Registry title
- EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENING TEST. (SUIVICOLO)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 2,000 people, planned
- Started
- 24 Mar 2026
- Expected to end
- 24 Oct 2028
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Usual care follow-up by CRCDC
- Information leaflet about colonoscopy follow-up
- Endorsement of CRCDC letters from the GP
- Record updated
- 18 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 50 to 75 in the Centre Val de Loire region of France who had a positive bowel cancer screening test. It tests earlier letters to help them have a colonoscopy.
- Age
- 50 to 75 years at the time of the positive screening test
- Sex
- All sexes can join
- Disease stage
- A positive colorectal cancer screening test. The result must have been sent to the person within 30 days of the test being read.
- Biomarker or test result
- A positive colorectal cancer screening test result
Main reasons for not taking part
- People who have refused to let their data be used for research are left out of the analyses
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Aged between 50 and 75 at the time of the positive colorectal cancer screening test; Residing in one of the departments of the Centre Val de Loire region; Date on which the positive CRC screening test result was sent to the beneficiary recorded; Colorectal cancer screening test results sent to the beneficiary within 30 days of the test being read; Affiliated with a health insurance fund
Who cannot take part
- Subjects who have notified their refusal to allow their data to be used for research purposes will be excluded from the analyses
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 75 years old?
Where in France
- Crcdc-CvlTours, FranceContact: Julie BOYARD, ScDTaking people
About the trial
What the trial wants to find out
To be effective, organized colorectal cancer screening requires good adherence to diagnostic colonoscopy in the event of a positive test. In France, the rate of diagnostic colonoscopy following a positive colorectal cancer screening test is less than 85%, and the median delay is close to 90 days. After receiving their positive result from the laboratory, individuals with no known follow-up are contacted only six months later by the Regional Cancer Screening Coordination Centers (CRCDC) responsible for following up with individuals who have tested positive. To optimize follow-up with colonoscopy, earlier contact and information about colonoscopy appear to be necessary. The contribution of the general practitioner identified on the test could be an additional lever.
Read full original descriptionShow less
The SUIVICOLO study aims to evaluate the effectiveness on the rate of colonoscopies performed at 6 months of two strategies for optimizing the follow-up of positive results in comparison with control group C (current procedures of the CRCDC Centre Val de Loire without early letter).
The two strategies evaluated will be:
* Group B1: Sending an early letter signed by the CRCDC accompanied by information leaflet about colonoscopy * Group B2: Sending an early letter co-signed by the CRCDC and the general practitioner (identified or provided by the patient on the test identification form) accompanied by information leaflet about colonoscopy.
These strategies will be compared to the current follow-up strategy in a three arm randomized controlled arm.
The 3 groups in the trial
- Control group (usual care)Existing treatment, for comparison
Treatment: Usual care follow-up by CRCDC
- Early letter with information leaflet about colonoscopyTreatment being tested
B1
Treatment: Usual care follow-up by CRCDC and Information leaflet about colonoscopy follow-up
- Early letter endorsed by the GP with information leaflet about colonoscopyTreatment being tested
B2
Treatment: Usual care follow-up by CRCDC, Information leaflet about colonoscopy follow-up, and Endorsement of CRCDC letters from the GP
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENING TEST, A RANDOMISED CONTROLLED TRIAL. (SUIVICOLO)
- Plain-language title
- Tests early letters to encourage follow-up colonoscopy after a positive bowel cancer screening testGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07520578, who can take part
- Record updated
- 18 September 2026